Hydrogel News and Research

RSS

InVivo Therapeutics reports net loss of $1,278,000 for first quarter 2011

InVivo Therapeutics, a medical device company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today reported financial results for the first quarter 2011.

16 May 2011

NIH funds Rice University study of new materials for growing replacement heart valves

A team of bioengineers from Rice University is bringing a promising new strategy for growing replacement heart valves closer to reality, thanks to a four-year, $1.2 million grant from the National Institutes of Health. The team hopes to use gel-like materials to generate three-dimensional patterns called scaffolds that can simultaneously mimic the complex structural and physical properties of heart-valve tissues and guide the behavior of tissue-forming cells.

21 Apr 2011

LecTec's cash and cash equivalent decreases to $8,689,280

LecTec Corporation announced today that it has released its fiscal 2010 financial information.

31 Mar 2011

USPTO grants patent to ULURU's Altrazeal product

ULURU Inc. announced today that it has been issued U.S. Patent 7,910,135 – Hydrogel Wound Dressing and Biomaterials Formed In Situ and Their Uses.

24 Mar 2011

Alliqua completes transdermal pain patch initial in vitro study for treatment of PHN

Alliqua, Inc., an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, announced today the successful completion of its initial in vitro permeation study for its transdermal pain patch project.

8 Mar 2011

First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has treated the first patient in a pilot clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

28 Feb 2011

BioTime to merge Glycosan with OrthoCyte

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.

14 Feb 2011

Ocular Therapeutix closes $14 million Series D financing round

Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures.

3 Feb 2011

Warwick research opens new strategy in vehicle design for drug release

The ability of some forms of plankton and bacteria to build an extra natural layer of nanoparticle-like armour has inspired chemists at the University of Warwick to devise a startlingly simple way to give drug bearing polymer vesicles (microscopic polymer based sacs of liquid) their own armoured protection.

31 Jan 2011

Alliqua completes transdermal pain patch initial study for treatment of PHN

Alliqua, an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, announced today the successful completion of its initial study for the transdermal pain patch project.

20 Jan 2011

Researcher tests new method of treatment for both humans and dogs with back trouble

Both humans and dogs can develop back problems. Slipped discs have similar symptoms and can be treated with the same methods regardless of whether the patient has two legs or four.

14 Jan 2011

Scientists create particles that resemble RBC, pave way for development of synthetic blood

A team of scientists has created particles that closely mirror some of the key properties of red blood cells, potentially helping pave the way for the development of synthetic blood.

11 Jan 2011

Neomend receives CE Mark for ProGEL PLATINUM Surgical Sealant

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received the European Union CE Mark for the company's ProGEL® PLATINUM Surgical Sealant.

10 Jan 2011

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients with osteoarthritis of the knee. Hydros and Hydros TA are next generation viscosupplement and viscosupplement/steroid combination products.

5 Jan 2011

LecTec announces postponement of trial date

LecTec Corporation announced that in the patent infringement litigation entitled LecTec Corporation v. Chattem, Inc. et al. the parties met with the appointed judge for the United States District Court for the Eastern District of Texas. LecTec was informed at such hearing that due to a pending, unrelated, criminal matter, the trial date would be postponed from January 4, 2011 to Monday January 10, 2011.

4 Jan 2011

Provectus commences PH-10 Phase 2c trial for psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.

14 Dec 2010

Hydrogel News and Research

InVivo Therapeutics reports net loss of $1,278,000 for first quarter 2011

NIH funds Rice University study of new materials for growing replacement heart valves

LecTec's cash and cash equivalent decreases to $8,689,280

USPTO grants patent to ULURU's Altrazeal product

Alliqua completes transdermal pain patch initial in vitro study for treatment of PHN

First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate

BioTime to merge Glycosan with OrthoCyte

Ocular Therapeutix closes $14 million Series D financing round

Warwick research opens new strategy in vehicle design for drug release

Alliqua completes transdermal pain patch initial study for treatment of PHN

Researcher tests new method of treatment for both humans and dogs with back trouble

Scientists create particles that resemble RBC, pave way for development of synthetic blood

Neomend receives CE Mark for ProGEL PLATINUM Surgical Sealant

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

LecTec announces postponement of trial date

Provectus commences PH-10 Phase 2c trial for psoriasis

Systagenix launches new innovative website

Study on animal model may impact treatment of stroke

Researchers identify molecular cascade that drives sprouting in brain after stroke

Researchers identify molecular cascade that drives process of reconnection in adult brain after stroke

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News